Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$64.54 USD

64.54
338,513

-0.71 (-1.09%)

Updated Jun 11, 2024 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe

J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR

NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR are part of the Zacks top Analyst Blog.

Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study

Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.

Sheraz Mian headshot

Top Stock Reports for NextEra Energy, BP & Gilead Sciences

Today's Research Daily features new research reports on 16 major stocks, including NextEra Energy, Inc. (NEE), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Hamilton Beach Brands Holding Company (HBB) and FONAR Corporation (FONR).

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Gilead (GILD) Announces Positive Interim Results on PBC Drug

Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know

Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.